Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

marketing campaigns

- PMLiVE

The words around health matter

The language used in healthcare can influence how people perceive their health, feel about themselves, and engage with treatments. Whole-person communication can help reduce stigma and support better real-world healthcare...

Mednet

- PMLiVE

The hidden work of turning breakthroughs into outcomes

The “problem” in healthcare comms is rarely what you say, it’s whether people can act on it. This article explains how we design whole-person engagement to turn intent into sustained...

Mednet

- PMLiVE

LEO Pharma to acquire Replay gene therapy platform

The acquisition will advance innovation for patients with rare skin diseases

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

- PMLiVE

Why pharma website projects stall long before compliance becomes the problem

Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...

Genetic Digital

- PMLiVE

PharmaQuest returns: EPA perspectives, through a rare disease lens

By Lottie Sequerra and Emily Morton-West

Amiculum

- PMLiVE

From text to context: Helping patients see side effects clearly

Discover how thoughtful design, clear language, and structured visuals can transform overwhelming side effect information into accessible, actionable insights for patients in our latest Health Literacy series.

Cuttsy + Cuttsy

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

Havas Life London unveils AI awareness campaign

The campaign highlights the dangers of AI misinformation in rare disease

- PMLiVE

What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

By Sarah Theobald

Amiculum

- PMLiVE

FDA approves first gene therapy for Wiskott-Aldrich syndrome

Symptoms of the rare disease include bleeding, eczema and frequent infections

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links